Scarica l'app Stockscreener
1.31
3.15%
0.04
Dopo l'orario di chiusura:
1.27
-0.04
-3.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Regulus Therapeutics Inc Borsa (RGLS) Ultime notizie
Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
10 Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat
Pre-market Movers In Healthcare Sector: ACER, AZRX, RUBY, ADTX, RGLS… - RTTNews
Checking in on Regulus Therapeutics Inc (RGLS) after recent insiders movement - Knox Daily
Is Regulus Therapeutics Inc (NASDAQ: RGLS) Stock Worth Investing In for High Returns? - Marketing Sentinel
RGLS’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Regulus Therapeutics Inc (RGLS) Stock: A Year of Highs and Lows - The InvestChronicle
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Morningstar
Regulus Therapeutics Inc. (NASDAQ:RGLS) Director David Baltimore Acquires 19,610 Shares - MarketBeat
Insider Buying: Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Acquires 50,000 Shares of Stock - MarketBeat
JPMorgan Chase & Co. Raises Stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Insider Moves Spark Interest: Is Regulus Therapeutics Set for a Comeback? - Jomfruland.net
Insiders Give Up US$8.7k As Regulus Therapeutics Stock Drops To US$1.00 - Yahoo Finance
CEO & Director of Regulus Therapeutics Joseph Hagan Buys 24% More Shares - Simply Wall St
Insider Buying: David Baltimore Acquires Shares of Regulus Thera - GuruFocus.com
Insider Buying: Joseph Hagan Acquires 50,000 Shares of Regulus T - GuruFocus.com
Regulus stock tumbles 24% amid study, regulatory updates - MSN
REVB Start 1B Trial and Announces Split - MSN
Regulus Therapeutics Shares Drop 24% Despite Positive ADPKD Tria - GuruFocus.com
Regulus Therapeutics Shares Drop 24% Despite Positive ADPKD Trial Data - Yahoo Finance
Regulus Therapeutics Kidney Disease Treatment Shows Response in Early-stage Trial -- Shares Fall - Marketscreener.com
Regulus stock tumbles 24% amid study, regulatory updates (RGLS:NASDAQ) - Seeking Alpha
Regulus reports progress in ADPKD trial and FDA talks - MSN
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429) - Citizentribune
Regulus Therapeutics (RGLS) Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen - StreetInsider.com
Regulus Therapeutics stock hits 52-week low at $1.16 - MSN
Regulus Therapeutics stock hits 52-week low at $1.16 By Investing.com - Investing.com South Africa
Barclays PLC Grows Stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics CFO sells shares worth $55,333 By Investing.com - Investing.com South Africa
Jane Street Group LLC Takes $46,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics president sells $39,721 in stock By Investing.com - Investing.com Australia
Regulus Therapeutics CEO sells shares worth $160,494 By Investing.com - Investing.com Canada
Regulus therapeutics executive sells shares worth $55,119 By Investing.com - Investing.com Nigeria
Insider Selling: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Sells 31,445 Shares of Stock - MarketBeat
Joseph P. Hagan Sells 115,290 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock - MarketBeat
Christopher Ray Aker Sells 38,547 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock - MarketBeat
Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Crispina Calsada Sells 38,716 Shares - MarketBeat
Regulus therapeutics executive sells shares worth $55,119 - Investing.com India
Regulus Therapeutics president sells $39,721 in stock - Investing.com
Regulus Therapeutics CFO sells shares worth $55,333 - Investing.com
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Consensus PT from Analysts - Defense World
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Geode Capital Management LLC Lowers Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Barclays PLC - Defense World
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by State Street Corp - Defense World
This Biotech Wasted No Time Stealing The Premarket Show - MSN
Regulus Therapeutics Announces Completion of Enrollment in Secon - GuruFocus.com
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average Target Price from Analysts - Defense World
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - The Eastern Progress Online
Institutional investors may overlook Regulus Therapeutics Inc.'s (NASDAQ:RGLS) recent US$12m market cap drop as long-term gains remain positive - Simply Wall St
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):